IMNN Imunon Inc

$IMNN so they only sold ThermoDox for glioblastoma and not the IMNN-001 for ovarian cancer, correct?

$IMNN Wow dropped below a $1 again after a recent 1 for 15 reverse stock split. And the market cap is $5M. What a s*** show! Unless MANAGEMENT has a partnership or buyout already inked they are a complete and colossal failure of epic proportions!!! If MANAGEMENT does another reverse stock split when the outstanding shares are only 6 million they should be immediately canned and fired! They should delist to OTC if this happens. They have already devastated and hurt shareholders enough with the previous reverse stock split.

$IMNN I hope you guys connected the dots from release yesterday. The glioblastoma piece is part of the Imunon National cancer institute collaboration so that’s going to be a free trial with no expenses. I wonder how many more spinoffs like that are possible?!?

$IMNN The only financing path forward - outside of an outright sale, which is the second most sensible thing to pursue - is to give up global non-US rights to an international pharma for some amount that can fund another year or two of trials. It may seem like a steep price for complete rights if the trial succeeds, but desperate times call for desperate measures. I've spent a lot of time uploading papers and other information to some of the smarter AI tools and there is a small chance that the trial does succeed despite what all the bears note here because there is a differentiated mechanism here unlike prior IL-12 attemps at gene therapy. 11:17 AM

$IMNN I’ve said this before and have obviously been proven wrong but I think we’re getting to the point that even the super stubborn ceo and chairman will HAVE to finally sell to stop the bleeding. Their runway is coming to an end.

$IMNN they have announced that they’re recruiting 0.5 patients /phase 3 site/month and had 27 patients a few months ago. I bet they’re at 50+ at this point. Not bad for a $6 mill market cap with a $16.5 mill agreement on your third line product.

$IMNN 2020 to 2026. 99% gone. Scam is an understatement. Slow death. Allowed to scam. Not investigated. Let to scam people. Will SEC investigate them?

$IMNN The deal announced yesterday is a free option, and any benefit the stock gets from this is due to option value. This is an asset Imunon is not currently using and was able to structure something that can only have upside and no downside. But what would really move the stock is a real deal on international rights for the main product.

$IMNN And the "why will they partner when they can buy this outright for pizza money" argument doesn't hold for international firms. Cross-border healthcare acquisition come under intense regulatory scrutiny (except a few big European or Japanese pharma firms). For most of them buyout of a US firm isn't an option they are interested in, but non-US global rights to something that can become first in line treatment will certainly be appealing. That's the group to talk to, and to be willing to sell the entire non-US rights for a very small amount now (say 30 million) to help develop the US market.

$IMNN $8 million market cap seems ridiculous for where they are. Ithink a reset to $150 million would be pretty rational

$IMNN Odd how Sleazy Statborg issued a statement during the big asset "sale", but nothing from any "voxeldox" executives, all of whom are so low rep, they can't be found anywhere. I do see that celsion has worked to flesh out the fake website that was only registered a month ago. So a company just appeared out of nowhere, run by nobody, with no discernible financing and saved celsion shares from free falling below$1. Immaculate timing if you ask me.

$IMNN is it possible the stock could go to a negative number like -$5 per share. So they’d actually pay you to buy it? Might bring some buyers

$IMNN Important decisions are looming for the company: either a capital raise funded by their friends, or one last desperate reverse split. Can anyone see any other way out for this management team? Honestly, seeing the Nasdaq delisting scenario play out all over again—due to the share price dropping below a dollar—makes me wonder: haven't Lindborg and company grown tired of this charade that’s been dragging on since the Termodox failure?

$IMNN They need to raise/dilute $30 Million, minimum, over the next 4 years. Not to mention what steps they'll need to take to keep in compliance. If this comp[any has such a great drug, a 5x current price buyout = 36M. That's less than chump change for BP. For some reason it doesn't seem very appealing to them.😕

$IMNN Nice opening! Will it get above a dollar by Christmas? No, I’ll ask Citizen, who’s daydreaming—he’s the one with the inside info.

$IMNN Ridiculous; it was as if the little mouse had given birth to an elephant, but in reality, it’s the elephant that’s given birth to a little mouse!!!! ... we’re still stuck at just over a dollar!! What kind of company is this, anyway?

$IMNN announced that it has entered into an agreement to sell its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. (“VoxelDox”). Under the agreement, VoxelDox intends to advance the development of ThermoDox for the treatment of glioblastoma multiforme (GBM), a difficult-to-treat form of brain cancer. In exchange, IMUNON will receive an equity ownership stake in VoxelDox, payments of up to $16.5 million contingent upon meeting development milestones and significant royalties on future net sales of ThermoDox product following commercial approval.

$IMNN Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001

$IMNN 🤝 IMUNON, Inc. agreed to sell its ThermoDox rights to VoxelDox Therapeutics, Inc., with future value tied to development milestones in a planned Phase 1 glioblastoma trial, to focus on its Phase 3 OVATION 3 trial of IMNN-001. Curated for market relevance

$IMNN It's a valid question that holds for any scenario that you and literally thousands of others have refused to answer over the last decade. I will give you credit, though, the vast majority of you just slip away silently having learned the hard way that which I informed them of day 1. At least you're here sort of admitting to throwing in the towel. Hopefully you learned something, although I doubt it.